European Pharmaceutical Law Review

Aims & Scope

The European Pharmaceutical Law Review (EPLR) identifies and analyses important legal and regulatory developments on the national, EU and international level.

Furthermore, it provides an overview of and critically examines judgments that shape the interpretation and application of EU pharmaceutical law and policy, in particular those by the European Courts, international courts and tribunals such as the WTO's Dispute Settlement Body, and higher national courts.

In order to establish itself as a forum for dialogue between different stakeholders in pharmaceutical regulation and governance, EPLR invites contributions from academics, practitioners, regulators and civil society representatives.

Topics covered by EPLR include: ● pharmaceutical law and policy in all jurisdictions (regional, national, international); ● Commission decisions (EMA opinions) and regulatory guidelines; ● national, EU, and international jurisprudence; ● medical devices; ● borderline cases: pharmaceuticals/food/cosmetics/chemicals ● patents /trademarks; ● health technology assessment and pricing/reimbursement;

View Aims & Scope

---

Metrics & Ranking

SJR (SCImago Journal Rank)

Year	Value
2024	0.151

Quartile

Year	Value
2024	Q3

h-index

Year	Value
2024	5

Journal Rank

Year	Value
2024	24457

Journal Citation Indicator

Year	Value
2024	10

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Pharmacology, Toxicology and Pharmaceutics and Social Sciences, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Homomorphic Encryption: The ‘Holy Grail’ for Big Data Analytics and Legal Compliance in the Pharmaceutical and Healthcare Sector?

  Citation: 14

  Authors: M., J., T., A., T., M.

• AI as a Medical Device: Is it Enough to Ensure Performance Transparency and Accountability?

  Citation: 13

  Authors: A.

• Lost on the High Seas without a Safe Harbor or a Shield? Navigating Cross-Border Transfers in the Pharmaceutical Sector After Schrems II Invalidation of the EU-US Privacy Shield

  Citation: 10

  Authors: M., T., C., M.

• ‘No-one is Safe Until Everyone is Safe’ – Patent Waiver, Compulsory Licensing and COVID-19

  Citation: 10

  Authors: B., J.

• How Much is Too Much? Defining the Metes and Bounds of Excessive Pricing in the Pharmaceutical Sector

  Citation: 6

  Authors: B., T.

• The EU-US Privacy Shield Regime for Cross-Border Transfers of Personal Data under the GDPR

  Citation: 5

  Authors: T., C., M., M.

• Biosimilars ∙ Regulatory Frameworks for Marketing Authorisation of Biosimilars: Where Do We Go From Here?

  Citation: 5

  Authors: E., A., I.

• Access to Medicines: The Interplay between Parallel Imports, Compulsory Licensing, and Voluntary Licensing

  Citation: 3

  Authors: L.

• Creating a European Health Data Space: Obstacles in Four Key Legal Areas

  Citation: 2

  Authors: A., P.

• A Commentary on Contact Proximity Tracing Apps in the Context of the EU Legal Framework for Medical Devices

  Citation: 2

  Authors: E., E.

---